

Nizoral^{TRADEMARK}

(ketoconazole) tablets

over 5 million
prescriptions
world-wide.

**Oral medication
in antifungal therapy:**



Doctors and patients around the world are discovering the modern simplicity of Nizoral oral therapy. Common but often problematic fungal infections can now be treated effectively and elegantly.

Typically, in *Candida* vaginitis, 2 oral tablets once daily for 5 days is all it takes today to effectively cure the problem.



**JANSSEN
PHARMACEUTICA**

the drug discovery company

Prescribing Information

Presentation: white, flat, half scored uncoated tablets marked "Janssen" on one side and K/200 on the reverse. Each tablet contains 200 mg ketoconazole. **Uses:** Nizoral is an orally active antimycotic for the treatment in adults of vaginal candidosis, superficial and systemic mycoses including dermatophyte and yeast infections of the skin, hair and nails, yeast infections of the mouth and G.I. tract. Also maintenance treatment of systemic mycoses and chronic mucocutaneous candidosis and prophylaxis in "at risk" patients. In children: systemic mycoses and severe local infections where previous topical treatment has failed. **Side effects, precautions, contra-indications:** contra-indicated in pregnancy. For maximal absorption Nizoral should be taken with meals. The use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H₂-blockers) should be avoided and, if indicated, such drugs should be taken not less than two hours after Nizoral. Nausea, skin rash, headache and pruritus may occasionally be observed. Alterations in liver function tests have occurred in patients on ketoconazole, these changes may be transient. Cases of hepatitis have been reported with an incidence of about 1 per 10,000 patients. Some of these may represent an idiosyncratic adverse reaction to the drug. This should be borne in mind in patients on long-term therapy. If a patient develops jaundice or any symptoms suggestive of hepatitis, treatment with ketoconazole should be stopped. Mild asymptomatic increases of liver enzyme levels, on the other hand, do not necessitate discontinuation of the treatment. Ketoconazole, when given together with cyclosporin A results in increased blood levels of cyclosporin A. It is important that blood levels of cyclosporin A are monitored if the two drugs are given concomitantly. Ketoconazole 200 mg once daily produces a transient decrease in plasma levels of testosterone. During long-term therapy at this dose, testosterone levels are usually not significantly different from controls. In rare instances, gynaecomastia has been reported.

International Medical Courses

Peripheral vascular disease

22 - 27 March 1987 in London

The course will cover all aspects of arterial, venous and lymphatic disease including pathology, diagnosis and treatment. There will be an emphasis on practical procedures with a workshop on non-invasive investigation and possibly a workshop of arterial anastomosis. The Directors of Studies will be **Professor N L Browse**, United Medical and Dental Schools of Guy's and St. Thomas', University of London, also Consultant Surgeon, St Thomas' Hospital, London, and **Mr K G Burnand**, Senior Lecturer, Department of Surgery, St. Thomas's Hospital Medical School.

The course is designed for surgeons, physicians and radiologists with an interest in peripheral vascular disease.

Fee £590

Human genetics: present and future

5 - 16 April 1987 in Oxford

The aim of the course is to inform physicians, graduates in biological science and Ph.D. students of the most recent advances in genetics, particularly in the field of human and medical genetics. Those attending the course are expected to have a good prior knowledge of basic genetics, to attend all lectures and to take an active part in the discussion which will follow the presentation of each topic. The course will be organized under the direction of **Professor M Adinolfi** and **Professor L Luzzatto**, Royal Postgraduate Medical School, University of London. The seminar is designed for physicians, graduates in biological sciences and Ph.D. students with a good basic knowledge of genetics.

Fee £640 Residential, £440 Non-residential.

The surgery of acute trauma

10 - 16 May 1987 in Birmingham

This is the first British Council course on this subject and will be directed by **Mr P C Bewes**, Secretary of the Institute of Accident Surgery and Consultant Surgeon at the Birmingham Accident Hospital. Some of the working sessions, including a visit to the Major Injuries Unit, will take place at the Institute of Accident Surgery.

The course is designed for clinicians with a major interest in trauma, especially consultant surgeons and senior trainees who have a clinical responsibility for managing accident cases. It will also be of interest to those planning for the reception of trauma victims and for accident services.

Fee £590 Residential, £385 Non-residential.

Cancer in children

31 May - 6 June 1987 in London

Rather than provide a coverage of all aspects of paediatric oncology, this course will focus on relevant laboratory research and on controversial areas in clinical practice. There will be a clinicopathological conference and one session will be devoted to selected presentations by course members. The Directors of Studies will be **Professor T J McElwain**, Department of Medicine, Institute of Cancer Research, University of London, and **Dr J Pritchard**, Senior Lecturer in Paediatric Oncology, Institute of Child Health, University of London.

The course is intended for paediatric oncologists, paediatricians and medical oncologists with several years' experience of the clinical management of cancer in children.

Fee £600 Residential, £400 Non-residential.

Paediatric nursing

28 June - 10 July 1987 in London

The purpose of this course, which is based at the Charles West School of Nursing, Hospital for Sick Children, Great Ormond Street, London is to provide an up-to-date review of special areas of paediatric nursing and of the changing pattern of care. In fields where knowledge is expanding, recent advances and potential developments will be reviewed and discussed. Course participants should have sufficient experience to enable them to contribute to discussions in the appropriate sessions. The course will be under the direction of **Miss B M Barchard**, Chief Nursing Officer and **Miss S Barlow**, Director of Nurse Education.

The course is open to senior nurses involved in the clinical, managerial and teaching aspects of paediatric nursing.

Fee £750 Residential, £485 Non-residential.

Further information and application forms are available from British Council Representatives overseas or from Courses Department, The British Council, 65 Davies Street, London W1Y 2AA.

The
British
Council

Trade Mark

Trade Mark
Power
daily cephalosporin

«Roceph» longer

The Roche logo, consisting of the word "ROCHE" in a bold, sans-serif font, enclosed within a hexagonal border.

Full details on composition, actions, contraindications, dosage and precautions are available on request.